MrC's Smallcap Sweeps for Oct 2022
Posted: October 3rd, 2022, 7:37 am
Smallcap Sweep. 03-Oct-22
SRT: I've been to the mountaintop and I have seen the promised jam.
Argentex (AGFX) guides FY-Dec ahead pf market expectations. Expects H1 rev £27.4m. Cites "more favourable market dynamics, with the recent historic lows in sterling presenting exceptional short-term trading conditions". [SP=89 Cap=101m]
Ince (INCE) agreed conditional heads of terms for the sale of two subsidiaries in Gibraltar, one of which for €500k net. [SP=4.2 Cap=11m]
Hipgnosis Songs Fund (SONG) refinancing of the debt facilities to 2027. [SP=88.94 Cap=1062m]
Hyve (HYVE) debt refinanced but at 7.75% over SONIA. Recovery has continued in Q4 in all markets with the exception of China where restrictions continue to disrupt. Bookings are over £65m. "This gives confidence in the FY23 outlook such that that the incremental debt service cost attributable to the increased margin over SONIA is expected to be offset by improved trading performance." [SP=52.5 Cap=153m]
Rosslyn Data Technologies (RDT) sells non-core Langdon Systems for £100k. [SP=2 Cap=7m]
Peel Hunt (PEEL) guides H1 rev c.£40.5m. "We have continued to invest in our business and make significant progress against our strategic priorities. This has been achieved against the backdrop of historically low levels of capital markets activity persisting market-wide." FY outlook for capital markets remains uncertain. [SP=87 Cap=107m]
Thruvision (THRU) one year framework contract from US Customs and Border Protection. Initial order $7m. The order size is ahead of mgmt expectations for FY23. [SP=22 Cap=32m]
CML Microsystems (CML) £1m share buyback. [SP=393.5 Cap=63m]
SRT Marine Systems (SRT) guides H1-Sep rev £18.8m and pretax £1.5m+. "Despite continuing production constraints, our transceivers business revenue grew by approximately 20% to £5.2m." [SP=26.2 Cap=47m]
Futura Medical (FUM) had completed all of the work that it believes is required for the FDA to grant marketing authorisation for MED3000, "Remains confident of being granted marketing authorisation by the FDA by the end of Q1 2023 in line with previously announced timelines." [SP=37 Cap=106m]
In line: RWI
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
SRT: I've been to the mountaintop and I have seen the promised jam.
Argentex (AGFX) guides FY-Dec ahead pf market expectations. Expects H1 rev £27.4m. Cites "more favourable market dynamics, with the recent historic lows in sterling presenting exceptional short-term trading conditions". [SP=89 Cap=101m]
Ince (INCE) agreed conditional heads of terms for the sale of two subsidiaries in Gibraltar, one of which for €500k net. [SP=4.2 Cap=11m]
Hipgnosis Songs Fund (SONG) refinancing of the debt facilities to 2027. [SP=88.94 Cap=1062m]
Hyve (HYVE) debt refinanced but at 7.75% over SONIA. Recovery has continued in Q4 in all markets with the exception of China where restrictions continue to disrupt. Bookings are over £65m. "This gives confidence in the FY23 outlook such that that the incremental debt service cost attributable to the increased margin over SONIA is expected to be offset by improved trading performance." [SP=52.5 Cap=153m]
Rosslyn Data Technologies (RDT) sells non-core Langdon Systems for £100k. [SP=2 Cap=7m]
Peel Hunt (PEEL) guides H1 rev c.£40.5m. "We have continued to invest in our business and make significant progress against our strategic priorities. This has been achieved against the backdrop of historically low levels of capital markets activity persisting market-wide." FY outlook for capital markets remains uncertain. [SP=87 Cap=107m]
Thruvision (THRU) one year framework contract from US Customs and Border Protection. Initial order $7m. The order size is ahead of mgmt expectations for FY23. [SP=22 Cap=32m]
CML Microsystems (CML) £1m share buyback. [SP=393.5 Cap=63m]
SRT Marine Systems (SRT) guides H1-Sep rev £18.8m and pretax £1.5m+. "Despite continuing production constraints, our transceivers business revenue grew by approximately 20% to £5.2m." [SP=26.2 Cap=47m]
Futura Medical (FUM) had completed all of the work that it believes is required for the FDA to grant marketing authorisation for MED3000, "Remains confident of being granted marketing authorisation by the FDA by the end of Q1 2023 in line with previously announced timelines." [SP=37 Cap=106m]
In line: RWI
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian